SCHEMBL30765922

SCHEMBL30765922

CCCCOC(=O)Cn1ccnc(N[C@@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
KMT2A Q03164 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 6/20 0.37
ALDH1A1 P00352 2/20 0.36
POLB P06746 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MCHR1 Q99705 1/20 0.36
MEN1 O00255 3/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SIRT3 Q9NTG7 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765920 0.86 L3MBTL1 (0.41) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30765521 0.86 KMT2A (0.38) LMNAKMT2AL3MBTL1MAPTALDH1A1
SCHEMBL30765468 0.86 LMNA (0.40) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30766075 0.85 HDAC6 (0.42) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30765802 0.84 GAA (0.40) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30765801 0.82 LMNA (0.41) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30765758 0.80 L3MBTL1 (0.40) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30765510 0.80 L3MBTL1 (0.41) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30765675 0.79 L3MBTL1 (0.40) LMNAKMT2AL3MBTL1GAAMAPT
SCHEMBL30765977 0.79 GAA (0.51) LMNAKMT2AL3MBTL1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed